All In Biotech

Drug Trial Radar · NCT02382939

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

92

Actual

Start

Feb 12, 2015

Primary completion

Jan 4, 2016

Study completion Jan 4, 2016

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Mar 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe and Asia. The aim of the trial is to compare the safety of once weekly dosing of somapacitan (administered with an investigational pen) with daily Norditropin® FlexPro® (somatropin delivered within a prefilled pen) for 26 weeks in previously human growth hormone (hGH) treated adults with growth hormone deficiency.

Conditions

  • Adult Growth Hormone Deficiency
  • Growth Hormone Disorder

Interventions

  • somapacitanDrug

    Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.

  • somatropinDrug

    Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: Weeks 0 - 26
  2. Incidence of Injection Site ReactionsTime frame: Weeks 0- 26

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Århus C, Denmark

  • Novo Nordisk Investigational Site

    København Ø, Denmark

  • Novo Nordisk Investigational Site

    Odense, Denmark

  • Novo Nordisk Investigational Site

    Angers, France

  • Novo Nordisk Investigational Site

    Brest, France

  • Novo Nordisk Investigational Site

    Bron, France

  • Novo Nordisk Investigational Site

    Dijon, France

  • Novo Nordisk Investigational Site

    Saint-Herblain, France

  • Novo Nordisk Investigational Site

    Aachen, Germany

  • Novo Nordisk Investigational Site

    Berlin, Germany

  • Novo Nordisk Investigational Site

    Frankfurt, Germany

  • Novo Nordisk Investigational Site

    Bunkyo-ku, Tokyo, Japan

  • Novo Nordisk Investigational Site

    Itabashi-ku, Tokyo, Japan

  • Novo Nordisk Investigational Site

    Izumo, Shimane, Japan

  • Novo Nordisk Investigational Site

    Kobe-shi, Hyogo, Japan

  • Novo Nordisk Investigational Site

    Kobe, Hyogo, Japan

  • Novo Nordisk Investigational Site

    Kyoto-shi Kyoto, Japan

  • Novo Nordisk Investigational Site

    Okayama, Okayama, Japan

  • Novo Nordisk Investigational Site

    Sagamihara-shi, Kanagawa, Japan

  • Novo Nordisk Investigational Site

    Gothenburg, Sweden

  • Novo Nordisk Investigational Site

    Lund, Sweden

  • Novo Nordisk Investigational Site

    Stockholm, Sweden

  • Novo Nordisk Investigational Site

    Birmingham, United Kingdom

  • Novo Nordisk Investigational Site

    Exeter, United Kingdom

  • Novo Nordisk Investigational Site

    Leeds, United Kingdom

  • Novo Nordisk Investigational Site

    London, United Kingdom

  • Novo Nordisk Investigational Site

    London, United Kingdom

  • Novo Nordisk Investigational Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.